

4. (Twice amended) The percutaneous absorption adhesive preparation according to claim 1 comprising the base drug salt of 0.1-20% by weight.
5. (Thrice amended) The percutaneous absorption adhesive preparation according to claim 1, wherein the organic acid salt is an acetic acid salt.
6. (Twice amended) The percutaneous absorption adhesive preparation according to claim 5, wherein the organic acid salt is sodium acetate.
7. (Amended) The percutaneous absorption adhesive preparation according to claim 2 comprising the organic acid salt of 0.01-15% by weight.
8. (Amended) The percutaneous absorption adhesive preparation according to claim 2 comprising the base drug salt of 0.1-20% by weight.
9. (Twice amended) The percutaneous absorption adhesive preparation according to claim 2, wherein the organic acid salt is an acetic acid salt.
10. (Twice amended) The percutaneous absorption adhesive preparation according to claim 9, wherein the organic acid salt is sodium acetate.
11. (Twice amended) The percutaneous absorption adhesive preparation according to claim 3, wherein the organic acid salt is an acetic acid salt.
12. (Twice amended) The percutaneous absorption adhesive preparation according to claim 11, wherein the organic acid salt is sodium acetate.

Remarks

Applicant has amended claims 1-12 so that the claims recite percutaneous absorption adhesive preparations. Support for the amendment is found in the "Technical Field" section on page 1 of the specification and the Abstract. No new matter has been added.